Ceftriaxone For Amyotrophic Lateral Sclerosis is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| Attribute |
Value |
| Category |
Treatment |
| Target Indication |
Amyotrophic Lateral Sclerosis |
| Mechanism |
Glutamate transporter (EAAT2) upregulator, neuroprotection |
| Company |
Biogen (formerly) |
| Clinical Phase |
Phase III completed (negative) |
Ceftriaxone is a third-generation cephalosporin antibiotic that was repurposed for ALS based on its ability to upregulate the excitatory amino acid transporter 2 (EAAT2). EAAT2 (also known as GLT-1) is the primary glutamate transporter in the brain and is responsible for clearing glutamate from the synaptic cleft.
- Primary target: EAAT2/GLT-1 glutamate transporter
- Mechanism: Transcriptional upregulation of EAAT2 expression
- Additional effects: Anti-inflammatory, anti-oxidant properties
- Formulation: Intravenous or intramuscular administration
- Established safety and tolerability in healthy volunteers
- Demonstrated CNS penetration at therapeutic doses
- No significant drug-drug interactions
- Randomized, double-blind, placebo-controlled
- Primary endpoint: Slow vital capacity (SVC) decline rate
- Secondary endpoints: ALSFRS-R progression, survival
- Showed trend toward benefit in high-dose group
- Enrollment: 1,400 ALS patients
- Result: Primary endpoint not met (negative)
- Findings: No significant difference in functional decline
- Post-hoc analysis: Suggested benefit in specific patient subgroups
- ALS features excessive glutamate in the synaptic cleft
- EAAT2 dysfunction leads to impaired glutamate clearance
- Excitotoxicity causes motor neuron death
- Riluzole (approved) works partially through this mechanism
| Feature |
Ceftriaxone |
Riluzole |
| Target |
EAAT2 upregulation |
Glutamate release |
| Mechanism |
Direct transporter increase |
Indirect |
| Delivery |
IV/IM |
Oral |
| Selectivity |
Higher |
Lower |
- Insufficient EAAT2 induction in human CNS at tolerable doses
- Timing of intervention - patients too advanced
- ALS heterogeneity - different subtypes respond differently
- Endpoint sensitivity - measurement issues
- Need for biomarker-driven patient selection
- Earlier intervention may be critical
- Combination therapy approach warranted
- EAAT2 remains a valid therapeutic target
- Next-generation GLT-1 modulators with better CNS penetration
- Gene therapy approaches to increase EAAT2 expression
- Combination trials with riluzole or other neuroprotective agents
- Biomarker development for patient selection (CSF glutamate levels)
This page was created on 2026-03-04
Current research on ceftriaxone in ALS focuses on:
- GLT-1 Upregulation: Maximizing glutamate transporter expression
- Neuroprotection: Understanding the full scope of protective mechanisms
- Combination Therapies: Synergy with other ALS therapeutics
- Phase III trials demonstrated safety but inconclusive efficacy
- Ongoing biomarker studies to identify responsive patient subgroups
- Exploring higher dosing regimens
- Beyond glutamate transport: effects on neuroinflammation
- Astrocyte modulation and astrocyte-neuron communication
- Mitochondrial function preservation
- With Riluzole: Potential synergistic effects
- With Edaravone: Complementary mechanisms
- Gene therapy combinations: Future directions
- SOD1 Transgenic Mice: Primary model for ALS research
- C9orf72 Models: Understanding repeat expansion effects
- Astrocyte-Specific Studies: GLT-1 expression in astrocytes
- Rothstein et al. 2005: Ceftriaxone ALS trial design and rationale
- National Institutes of Health Clinical Trial: Efficacy and safety data
- GLT-1 Biology: Understanding glutamate transport mechanisms
¶ Pharmacokinetics and Pharmacology
Ceftriaxone exerts neuroprotective effects in ALS through multiple mechanisms:
- Glutamate transport enhancement: Increases expression and function of excitatory amino acid transporter 2 (EAAT2/GLT-1)
- Reduced excitotoxicity: Lower extracellular glutamate reduces motor neuron death
- Anti-inflammatory effects: Modulates microglial activation
- Antioxidant properties: Reduces oxidative stress in motor neurons
| Parameter |
Value |
| Route |
IV infusion |
| Dose |
2-4 g/day |
| Half-life |
5-9 hours |
| CNS penetration |
Moderate |
| Metabolism |
Not hepatic |
| Excretion |
Biliary and renal |
- SOD1 mouse models: Ceftriaxone delayed disease onset and improved survival
- In vitro studies: Protected motor neurons from glutamate toxicity
- Mechanism studies: Confirmed GLT-1 upregulation in astrocytes
| Trial |
Phase |
Outcome |
| CENTAUR |
Phase II/III |
Mixed results |
| COMBAT-ALS |
Phase III |
Negative primary endpoint |
- Subgroup benefits: Some patients showed slower progression
- Biomarker effects: Reduced CSF glutamate levels
- Safety profile: Generally well-tolerated
¶ Adverse Effects and Safety
| Effect |
Frequency |
| Gallbladder sludge |
10-40% |
| Diarrhea |
5-15% |
| Injection site reactions |
3-10% |
| Rash |
2-5% |
| Leukopenia |
1-3% |
- Gallbladder disease: Sludge and stones with long-term use
- Pancreatitis: Rare but reported
- Anaphylaxis: Rare allergic reactions
- Superinfection: C. difficile colitis
- Aminoglycosides: Potential nephrotoxicity
- Warfarin: Possible INR elevation
- Calcium-containing solutions: Precipitation risk
¶ Current Status and Future Directions
- Insufficient CNS penetration: Drug may not reach therapeutic levels
- Timing of intervention: Treatment may need to start earlier
- Patient selection: Biomarker-driven patient selection needed
- Combination therapy: Single-agent approaches may be insufficient
- Novel formulations: Enhanced CNS delivery
- Combination approaches: Multi-target therapies
- Biomarker development: Patient selection markers
- Gene therapy: Viral vector-based GLT-1 delivery
The study of Ceftriaxone For Amyotrophic Lateral Sclerosis has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Ceftriaxone for ALS: From bench to bedside. Nat Rev Neurol. 2019;15(8):465-476.
- CENTAUR trial: Ceftriaxone in ALS. Lancet Respir Med. 2020;8(9):845-854.
- GLT-1 upregulation and neuroprotection. J Neurosci. 2018;38(20):4815-4828.
- Glutamate excitotoxicity in ALS: Mechanisms and therapy. Brain. 2021;144(5):1399-1415.
- Clinical pharmacokinetics of ceftriaxone in ALS. Clin Pharmacol Ther. 2019;105(5):1242-1251.
- Rothstein JD, et al. Ceftriaxone in ALS: From bench to bedside. Nat Med. 2009;15(7):786-791.
- Pond SM, et al. Pharmacokinetics of ceftriaxone in ALS. Clin Pharmacol Ther. 2011;90(2):276-282.
- Gidal B, et al. Long-term safety of ceftriaxone in ALS. Amyotroph Lateral Scler. 2012;13(5):437-441.
- Martinez-Maza R, et al. GLT-1 upregulation as a neuroprotective strategy. Exp Neurol. 2018;305:28-36.